Literature DB >> 16773433

Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis.

Albert J Czaja1, Herschel A Carpenter.   

Abstract

Thiopurine methyltransferase deficiency has been associated with intolerance to azathioprine. Our goals were to assess the frequency of enzyme deficiency in autoimmune hepatitis and correlate deficiency states with azathioprine intolerance. Eighty-six patients receiving azathioprine (50-150 mg daily) were evaluated for enzyme activity and azathioprine-related complications. Their findings were compared to 89 similarly treated but untested patients. Thirteen patients (15%) had low thiopurine methyltransferase levels (11.4+/- 0.9 U/ml RBC; range, 3.5-14.9 U/ml RBC). Azathioprine intolerance occurred as commonly in patients with normal or above normal enzyme levels as in patients with below normal levels (12% versus 15%, p = 0.7). Patients treated without enzyme testing had the same frequency of complications (9% versus 13%, p = 0.5) as tested patients. We conclude that routine screening of blood thiopurine methyltransferase levels has a low yield for identifying individual patients at risk for azathioprine toxicity during conventional low dose therapy for autoimmune hepatitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16773433     DOI: 10.1007/s10620-006-9336-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  15 in total

Review 1.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy.

Authors:  Gary R Lichtenstein
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

3.  6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

Authors:  Marla C Dubinsky; Huiying Yang; Philip V Hassard; Ernest G Seidman; Lori Y Kam; Maria T Abreu; Stephan R Targan; Eric A Vasiliauskas
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

4.  Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity.

Authors:  L Lennard; J C Welch; J S Lilleyman
Journal:  Br J Clin Pharmacol       Date:  1997-11       Impact factor: 4.335

Review 5.  Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.

Authors:  H L McLeod; E Y Krynetski; M V Relling; W E Evans
Journal:  Leukemia       Date:  2000-04       Impact factor: 11.528

6.  Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease.

Authors:  Carmen Cuffari; Themistocles Dassopoulos; Lisa Turnbough; Richard E Thompson; Theodore M Bayless
Journal:  Clin Gastroenterol Hepatol       Date:  2004-05       Impact factor: 11.382

7.  Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine.

Authors:  A J Black; H L McLeod; H A Capell; R H Powrie; L K Matowe; S C Pritchard; E S Collie-Duguid; D M Reid
Journal:  Ann Intern Med       Date:  1998-11-01       Impact factor: 25.391

8.  Azathioprine for long-term maintenance of remission in autoimmune hepatitis.

Authors:  P J Johnson; I G McFarlane; R Williams
Journal:  N Engl J Med       Date:  1995-10-12       Impact factor: 91.245

9.  Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis.

Authors:  Peter G Langley; James Underhill; J Michael Tredger; Suzanne Norris; Ian G McFarlane
Journal:  J Hepatol       Date:  2002-10       Impact factor: 25.083

10.  Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease.

Authors:  Miguel Regueiro; Houssam Mardini
Journal:  J Clin Gastroenterol       Date:  2002-09       Impact factor: 3.062

View more
  13 in total

Review 1.  Autoimmune hepatitis.

Authors:  Farhad Sahebjam; John M Vierling
Journal:  Front Med       Date:  2015-03-06       Impact factor: 4.592

Review 2.  Current concepts in the diagnosis and management of autoimmune hepatitis.

Authors:  Stephen Kriese; Michael A Heneghan
Journal:  Frontline Gastroenterol       Date:  2012-11-12

Review 3.  Difficult treatment decisions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

Review 4.  Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management.

Authors:  Syed Rizvi; Samer Gawrieh
Journal:  Drugs Aging       Date:  2018-07       Impact factor: 3.923

5.  Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management.

Authors:  Ye H Oo; Stefan G Hubscher; David H Adams
Journal:  Hepatol Int       Date:  2010-05-19       Impact factor: 6.047

Review 6.  Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly.

Authors:  Albert J Czaja
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 7.  Clinical features and management of autoimmune hepatitis.

Authors:  Edward-L Krawitt
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

8.  Predictors of azathioprine toxicity in children with autoimmune hepatitis.

Authors:  Behairy El-Sayed Behairy; Hala Hany El-Said; Hatem Abd-Alsattar Konswa; Ahmed El-Sayed Nour El-Deen; Nermin Mohamed Adawy; Ahmad Mohamed Sira
Journal:  Clin Exp Hepatol       Date:  2021-03-25

Review 9.  Diagnosis and treatment of autoimmune hepatitis.

Authors:  John M Vierling
Journal:  Curr Gastroenterol Rep       Date:  2012-02

Review 10.  Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions.

Authors:  Albert J Czaja
Journal:  Gut Liver       Date:  2016-03       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.